Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 130 entries
Sorted by: Best Match Show Resources per page
Gender differences in cochlear response time: An explanation for gender amplitude differences in the unmasked auditory brain‐stem response

STEM and gender

Eggermont JJ, Ponton CW.
GSID: s6GTTjKcFTIJ
M Don, CW Ponton, JJ Eggermont… - The Journal of the …, 1993 - asa.scitation.org

… Our results suggest that there are significant gender differences in cochlear response times across the cochlea that may be responsible for gender differences in wave V amplitude for …

Cite
Don, M., Ponton, C. W., Eggermont, J. J., & Masuda, A. (1993). Gender differences in cochlear response time: An explanation for gender amplitude differences in the unmasked auditory brain‐stem response. The Journal of the Acoustical Society of America, 94(4), 2135-2148.
Don, Manuel, et al. "Gender differences in cochlear response time: An explanation for gender amplitude differences in the unmasked auditory brain‐stem response." The Journal of the Acoustical Society of America 94.4 (1993): 2135-2148.
Copy Download .nbib Format: MLA
Management of psychiatric adverse events with immunotherapy with interferon-alfa.

Acta neuropsychiatrica

Van Gool AR, Kruit WH, Cornelissen JJ, Berk L, Eggermont AM, Bannink M.
PMID: 26976539
Acta Neuropsychiatr. 1999 Dec;11(4):120-4. doi: 10.1017/S0924270800035857.

Immunotherapy with interferon-alfa has become standard therapy in selected patients with viral hepatitis and chronic myelogenous leukemia. In addition, it is used in a variety of other diseases, both as standard therapy and in clinical trials. Its use is...

Cite
Van Gool AR, Kruit WH, Cornelissen JJ, et al. Management of psychiatric adverse events with immunotherapy with interferon-alfa. Acta Neuropsychiatr. 1999;11(4):120-4doi: 10.1017/S0924270800035857.
Van Gool, A. R., Kruit, W. H., Cornelissen, J. J., Berk, L., Eggermont, A. M., & Bannink, M. (1999). Management of psychiatric adverse events with immunotherapy with interferon-alfa. Acta neuropsychiatrica, 11(4), 120-4. https://doi.org/10.1017/S0924270800035857
Van Gool, A R, et al. "Management of psychiatric adverse events with immunotherapy with interferon-alfa." Acta neuropsychiatrica vol. 11,4 (1999): 120-4. doi: https://doi.org/10.1017/S0924270800035857
Van Gool AR, Kruit WH, Cornelissen JJ, Berk L, Eggermont AM, Bannink M. Management of psychiatric adverse events with immunotherapy with interferon-alfa. Acta Neuropsychiatr. 1999 Dec;11(4):120-4. doi: 10.1017/S0924270800035857. PMID: 26976539.
Copy Download .nbib Format: NLM
Doubling the blockade for melanoma immunotherapy.

Oncoimmunology

Galluzzi L, Eggermont A, Kroemer G.
PMID: 26942094
Oncoimmunology. 2015 Oct 29;5(1):e1106127. doi: 10.1080/2162402X.2015.1106127. eCollection 2016.

No abstract available.

Cite
Galluzzi L, Eggermont A, Kroemer G. Doubling the blockade for melanoma immunotherapy. Oncoimmunology. 2015;5(1):e1106127doi: 10.1080/2162402X.2015.1106127.
Galluzzi, L., Eggermont, A., & Kroemer, G. (2016). Doubling the blockade for melanoma immunotherapy. Oncoimmunology, 5(1), e1106127. https://doi.org/10.1080/2162402X.2015.1106127
Galluzzi, Lorenzo, et al. "Doubling the blockade for melanoma immunotherapy." Oncoimmunology vol. 5,1 (2016): e1106127. doi: https://doi.org/10.1080/2162402X.2015.1106127
Galluzzi L, Eggermont A, Kroemer G. Doubling the blockade for melanoma immunotherapy. Oncoimmunology. 2015 Oct 29;5(1):e1106127. doi: 10.1080/2162402X.2015.1106127. eCollection 2016. PMID: 26942094; PMCID: PMC4760293.
Copy Download .nbib Format: NLM
Trial watch: Naked and vectored DNA-based anticancer vaccines.

Oncoimmunology

Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 26155408
Oncoimmunology. 2015 Apr 02;4(5):e1026531. doi: 10.1080/2162402X.2015.1026531. eCollection 2015 May.

One type of anticancer vaccine relies on the administration of DNA constructs encoding one or multiple tumor-associated antigens (TAAs). The ultimate objective of these preparations, which can be naked or vectored by non-pathogenic viruses, bacteria or yeast cells, is...

Cite
Bloy N, Buqué A, Aranda F, et al. Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology. 2015;4(5):e1026531doi: 10.1080/2162402X.2015.1026531.
Bloy, N., Buqué, A., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Sautès-Fridman, C., Fucikova, J., Galon, J., Spisek, R., Tartour, E., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2015). Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology, 4(5), e1026531. https://doi.org/10.1080/2162402X.2015.1026531
Bloy, Norma, et al. "Trial watch: Naked and vectored DNA-based anticancer vaccines." Oncoimmunology vol. 4,5 (2015): e1026531. doi: https://doi.org/10.1080/2162402X.2015.1026531
Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology. 2015 Apr 02;4(5):e1026531. doi: 10.1080/2162402X.2015.1026531. eCollection 2015 May. PMID: 26155408; PMCID: PMC4485755.
Copy Download .nbib Format: NLM
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Oncoimmunology

Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 25949870
Oncoimmunology. 2015 Feb 03;4(1):e985940. doi: 10.4161/2162402X.2014.985940. eCollection 2015 Jan.

An expanding panel of monoclonal antibodies (mAbs) that specifically target malignant cells or intercept trophic factors delivered by the tumor stroma is now available for cancer therapy. These mAbs can exert direct antiproliferative/cytotoxic effects as they inhibit pro-survival signal...

Cite
Vacchelli E, Pol J, Bloy N, et al. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology. 2015;4(1):e985940doi: 10.4161/2162402X.2014.985940.
Vacchelli, E., Pol, J., Bloy, N., Eggermont, A., Cremer, I., Fridman, W. H., Galon, J., Marabelle, A., Kohrt, H., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2015). Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology, 4(1), e985940. https://doi.org/10.4161/2162402X.2014.985940
Vacchelli, Erika, et al. "Trial watch: Tumor-targeting monoclonal antibodies for oncological indications." Oncoimmunology vol. 4,1 (2015): e985940. doi: https://doi.org/10.4161/2162402X.2014.985940
Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology. 2015 Feb 03;4(1):e985940. doi: 10.4161/2162402X.2014.985940. eCollection 2015 Jan. PMID: 25949870; PMCID: PMC4368132.
Copy Download .nbib Format: NLM
BIOFRAG - a new database for analyzing BIOdiversity responses to forest FRAGmentation.

Ecology and evolution

Pfeifer M, Lefebvre V, Gardner TA, Arroyo-Rodriguez V, Baeten L, Banks-Leite C, Barlow J, Betts MG, Brunet J, Cerezo A, Cisneros LM, Collard S, D'Cruze N, da Silva Motta C, Duguay S, Eggermont H, Eigenbrod F, Hadley AS, Hanson TR, Hawes JE, Heartsill Scalley T, Klingbeil BT, Kolb A, Kormann U, Kumar S, Lachat T, Lakeman Fraser P, Lantschner V, Laurance WF, Leal IR, Lens L, Marsh CJ, Medina-Rangel GF, Melles S, Mezger D, Oldekop JA, Overal WL, Owen C, Peres CA, Phalan B, Pidgeon AM, Pilia O, Possingham HP, Possingham ML, Raheem DC, Ribeiro DB, Ribeiro Neto JD, Douglas Robinson W, Robinson R, Rytwinski T, Scherber C, Slade EM, Somarriba E, Stouffer PC, Struebig MJ, Tylianakis JM, Tscharntke T, Tyre AJ, Urbina Cardona JN, Vasconcelos HL, Wearn O, Wells K, Willig MR, Wood E, Young RP, Bradley AV, Ewers RM.
PMID: 24967073
Ecol Evol. 2014 May;4(9):1524-37. doi: 10.1002/ece3.1036. Epub 2014 Mar 27.

Habitat fragmentation studies have produced complex results that are challenging to synthesize. Inconsistencies among studies may result from variation in the choice of landscape metrics and response variables, which is often compounded by a lack of key statistical or...

Cite
Pfeifer M, Lefebvre V, Gardner TA, et al. BIOFRAG - a new database for analyzing BIOdiversity responses to forest FRAGmentation. Ecol Evol. 2014;4(9):1524-37doi: 10.1002/ece3.1036.
Pfeifer, M., Lefebvre, V., Gardner, T. A., Arroyo-Rodriguez, V., Baeten, L., Banks-Leite, C., Barlow, J., Betts, M. G., Brunet, J., Cerezo, A., Cisneros, L. M., Collard, S., D'Cruze, N., da Silva Motta, C., Duguay, S., Eggermont, H., Eigenbrod, F., Hadley, A. S., Hanson, T. R., Hawes, J. E., Heartsill Scalley, T., Klingbeil, B. T., Kolb, A., Kormann, U., Kumar, S., Lachat, T., Lakeman Fraser, P., Lantschner, V., Laurance, W. F., Leal, I. R., Lens, L., Marsh, C. J., Medina-Rangel, G. F., Melles, S., Mezger, D., Oldekop, J. A., Overal, W. L., Owen, C., Peres, C. A., Phalan, B., Pidgeon, A. M., Pilia, O., Possingham, H. P., Possingham, M. L., Raheem, D. C., Ribeiro, D. B., Ribeiro Neto, J. D., Douglas Robinson, W., Robinson, R., Rytwinski, T., Scherber, C., Slade, E. M., Somarriba, E., Stouffer, P. C., Struebig, M. J., Tylianakis, J. M., Tscharntke, T., Tyre, A. J., Urbina Cardona, J. N., Vasconcelos, H. L., Wearn, O., Wells, K., Willig, M. R., Wood, E., Young, R. P., Bradley, A. V., & Ewers, R. M. (2014). BIOFRAG - a new database for analyzing BIOdiversity responses to forest FRAGmentation. Ecology and evolution, 4(9), 1524-37. https://doi.org/10.1002/ece3.1036
Pfeifer, Marion, et al. "BIOFRAG - a new database for analyzing BIOdiversity responses to forest FRAGmentation." Ecology and evolution vol. 4,9 (2014): 1524-37. doi: https://doi.org/10.1002/ece3.1036
Pfeifer M, Lefebvre V, Gardner TA, Arroyo-Rodriguez V, Baeten L, Banks-Leite C, Barlow J, Betts MG, Brunet J, Cerezo A, Cisneros LM, Collard S, D'Cruze N, da Silva Motta C, Duguay S, Eggermont H, Eigenbrod F, Hadley AS, Hanson TR, Hawes JE, Heartsill Scalley T, Klingbeil BT, Kolb A, Kormann U, Kumar S, Lachat T, Lakeman Fraser P, Lantschner V, Laurance WF, Leal IR, Lens L, Marsh CJ, Medina-Rangel GF, Melles S, Mezger D, Oldekop JA, Overal WL, Owen C, Peres CA, Phalan B, Pidgeon AM, Pilia O, Possingham HP, Possingham ML, Raheem DC, Ribeiro DB, Ribeiro Neto JD, Douglas Robinson W, Robinson R, Rytwinski T, Scherber C, Slade EM, Somarriba E, Stouffer PC, Struebig MJ, Tylianakis JM, Tscharntke T, Tyre AJ, Urbina Cardona JN, Vasconcelos HL, Wearn O, Wells K, Willig MR, Wood E, Young RP, Bradley AV, Ewers RM. BIOFRAG - a new database for analyzing BIOdiversity responses to forest FRAGmentation. Ecol Evol. 2014 May;4(9):1524-37. doi: 10.1002/ece3.1036. Epub 2014 Mar 27. PMID: 24967073; PMCID: PMC4063456.
Copy Download .nbib Format: NLM
Trial watch: Dendritic cell-based anticancer therapy.

Oncoimmunology

Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman WH, Fučíková J, Galon J, Tartour E, Spisek R, Dhodapkar MV, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 25941593
Oncoimmunology. 2014 Dec 21;3(11):e963424. doi: 10.4161/21624011.2014.963424. eCollection 2014 Nov.

The use of patient-derived dendritic cells (DCs) as a means to elicit therapeutically relevant immune responses in cancer patients has been extensively investigated throughout the past decade. In this context, DCs are generally expanded, exposed to autologous tumor cell...

Cite
Bloy N, Pol J, Aranda F, et al. Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology. 2014;3(11):e963424doi: 10.4161/21624011.2014.963424.
Bloy, N., Pol, J., Aranda, F., Eggermont, A., Cremer, I., Fridman, W. H., Fučíková, J., Galon, J., Tartour, E., Spisek, R., Dhodapkar, M. V., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014). Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology, 3(11), e963424. https://doi.org/10.4161/21624011.2014.963424
Bloy, Norma, et al. "Trial watch: Dendritic cell-based anticancer therapy." Oncoimmunology vol. 3,11 (2014): e963424. doi: https://doi.org/10.4161/21624011.2014.963424
Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman WH, Fučíková J, Galon J, Tartour E, Spisek R, Dhodapkar MV, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology. 2014 Dec 21;3(11):e963424. doi: 10.4161/21624011.2014.963424. eCollection 2014 Nov. PMID: 25941593; PMCID: PMC4292311.
Copy Download .nbib Format: NLM
Metastatic melanoma: New paradigms of treatment and new toxicities.

EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.]

Robert C, Mateus C, Routier E, Thomas M, Boussemart L, Eggermont AM.
PMID: 26217144
EJC Suppl. 2013 Sep;11(2):278-80. doi: 10.1016/j.ejcsup.2013.07.046.

No abstract available.

Cite
Robert C, Mateus C, Routier E, et al. Metastatic melanoma: New paradigms of treatment and new toxicities. EJC Suppl. 2013;11(2):278-80doi: 10.1016/j.ejcsup.2013.07.046.
Robert, C., Mateus, C., Routier, E., Thomas, M., Boussemart, L., & Eggermont, A. M. (2013). Metastatic melanoma: New paradigms of treatment and new toxicities. EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.], 11(2), 278-80. https://doi.org/10.1016/j.ejcsup.2013.07.046
Robert, Caroline, et al. "Metastatic melanoma: New paradigms of treatment and new toxicities." EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.] vol. 11,2 (2013): 278-80. doi: https://doi.org/10.1016/j.ejcsup.2013.07.046
Robert C, Mateus C, Routier E, Thomas M, Boussemart L, Eggermont AM. Metastatic melanoma: New paradigms of treatment and new toxicities. EJC Suppl. 2013 Sep;11(2):278-80. doi: 10.1016/j.ejcsup.2013.07.046. PMID: 26217144; PMCID: PMC4041186.
Copy Download .nbib Format: NLM
[Congenital malformations. Anatomoclinical report on some cases].

Belgisch tijdschrift voor geneeskunde

BONTE J, LAUWERYNS J, EGGERMONT E.
PMID: 13802620
Belg Tijdschr Geneesk. 1960 Aug 01;16:737-43.

No abstract available.

Cite
BONTE J, LAUWERYNS J, EGGERMONT E. [Congenital malformations. Anatomoclinical report on some cases]. Belg Tijdschr Geneesk. 1960;16:737-43
BONTE, J., LAUWERYNS, J., & EGGERMONT, E. (1960). [Congenital malformations. Anatomoclinical report on some cases]. Belgisch tijdschrift voor geneeskunde, 16737-43.
BONTE, J, et al. "[Congenital malformations. Anatomoclinical report on some cases]." Belgisch tijdschrift voor geneeskunde vol. 16 (1960): 737-43.
BONTE J, LAUWERYNS J, EGGERMONT E. [Congenital malformations. Anatomoclinical report on some cases]. Belg Tijdschr Geneesk. 1960 Aug 01;16:737-43. Dutch. PMID: 13802620.
Copy Download .nbib Format: NLM
Standard two-compartment formulation for total parenteral nutrition in the neonatal intensive care unit: A fluid tolerance based system.

Clinical nutrition (Edinburgh, Scotland)

Devlieger H, De Pourcq L, Casneuf A, Vanhole C, de Zegher F, Jaeken J, Eggermont E.
PMID: 16843327
Clin Nutr. 1993 Oct;12(5):282-6. doi: 10.1016/0261-5614(93)90047-8.

The nutrient requirements of most (pre) term newborns receiving intensive care appear to be relatively fixed. The range of optimal fluid load however, is perceived as being quite narrow and highly variable in time. We designed four amino acid-dextrose...

Cite
Devlieger H, De Pourcq L, Casneuf A, et al. Standard two-compartment formulation for total parenteral nutrition in the neonatal intensive care unit: A fluid tolerance based system. Clin Nutr. 1993;12(5):282-6doi: 10.1016/0261-5614(93)90047-8.
Devlieger, H., De Pourcq, L., Casneuf, A., Vanhole, C., de Zegher, F., Jaeken, J., & Eggermont, E. (1993). Standard two-compartment formulation for total parenteral nutrition in the neonatal intensive care unit: A fluid tolerance based system. Clinical nutrition (Edinburgh, Scotland), 12(5), 282-6. https://doi.org/10.1016/0261-5614(93)90047-8
Devlieger, H, et al. "Standard two-compartment formulation for total parenteral nutrition in the neonatal intensive care unit: A fluid tolerance based system." Clinical nutrition (Edinburgh, Scotland) vol. 12,5 (1993): 282-6. doi: https://doi.org/10.1016/0261-5614(93)90047-8
Devlieger H, De Pourcq L, Casneuf A, Vanhole C, de Zegher F, Jaeken J, Eggermont E. Standard two-compartment formulation for total parenteral nutrition in the neonatal intensive care unit: A fluid tolerance based system. Clin Nutr. 1993 Oct;12(5):282-6. doi: 10.1016/0261-5614(93)90047-8. PMID: 16843327.
Copy Download .nbib Format: NLM
Regional administration of recombinant tumour necrosis factor-alpha in cancer, with special reference to melanoma.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Lejeune F, Liénard D, Eggermont A.
PMID: 18020561
BioDrugs. 1998 Mar;9(3):211-8. doi: 10.2165/00063030-199809030-00004.

Recombinant tumour necrosis factor-alpha (rTNFalpha) possesses the unique property of activating and selectively destroying the tumour-associated microvasculature. Systemic application of rTNFalpha has shown that the maximum tolerated dose (MTD) is 10 times lower than the efficient dose in animals....

Cite
Lejeune F, Liénard D, Eggermont A. Regional administration of recombinant tumour necrosis factor-alpha in cancer, with special reference to melanoma. BioDrugs. 1998;9(3):211-8doi: 10.2165/00063030-199809030-00004.
Lejeune, F., Liénard, D., & Eggermont, A. (1998). Regional administration of recombinant tumour necrosis factor-alpha in cancer, with special reference to melanoma. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 9(3), 211-8. https://doi.org/10.2165/00063030-199809030-00004
Lejeune, F, et al. "Regional administration of recombinant tumour necrosis factor-alpha in cancer, with special reference to melanoma." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 9,3 (1998): 211-8. doi: https://doi.org/10.2165/00063030-199809030-00004
Lejeune F, Liénard D, Eggermont A. Regional administration of recombinant tumour necrosis factor-alpha in cancer, with special reference to melanoma. BioDrugs. 1998 Mar;9(3):211-8. doi: 10.2165/00063030-199809030-00004. PMID: 18020561.
Copy Download .nbib Format: NLM
Exercise and early-onset Alzheimer's disease: theoretical considerations.

Dementia and geriatric cognitive disorders extra

Hooghiemstra AM, Eggermont LH, Scheltens P, van der Flier WM, Scherder EJ.
PMID: 22590474
Dement Geriatr Cogn Dis Extra. 2012 Jan;2:132-45. doi: 10.1159/000335493. Epub 2012 Apr 14.

BACKGROUND/AIMS: Although studies show a negative relationship between physical activity and the risk for cognitive impairment and late-onset Alzheimer's disease, studies concerning early-onset Alzheimer's disease (EOAD) are lacking. This review aims to justify the value of exercise interventions in...

Cite
Hooghiemstra AM, Eggermont LH, Scheltens P, et al. Exercise and early-onset Alzheimer's disease: theoretical considerations. Dement Geriatr Cogn Dis Extra. 2012;2:132-45doi: 10.1159/000335493.
Hooghiemstra, A. M., Eggermont, L. H., Scheltens, P., van der Flier, W. M., & Scherder, E. J. (2012). Exercise and early-onset Alzheimer's disease: theoretical considerations. Dementia and geriatric cognitive disorders extra, 2132-45. https://doi.org/10.1159/000335493
Hooghiemstra, Astrid M, et al. "Exercise and early-onset Alzheimer's disease: theoretical considerations." Dementia and geriatric cognitive disorders extra vol. 2 (2012): 132-45. doi: https://doi.org/10.1159/000335493
Hooghiemstra AM, Eggermont LH, Scheltens P, van der Flier WM, Scherder EJ. Exercise and early-onset Alzheimer's disease: theoretical considerations. Dement Geriatr Cogn Dis Extra. 2012 Jan;2:132-45. doi: 10.1159/000335493. Epub 2012 Apr 14. PMID: 22590474; PMCID: PMC3347875.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 130 entries